14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Insider Trading

$38.22
+0 (+0%)
At Close: May 27, 2022

Dicerna Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 12 087 and sold 8 528 928 DRNA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
0
Buy 12 087 Shares
Sell 8 528 928 Shares

Historical Insider Trades

Date Type Action Person Amount
Dec 28, 2021 Common Stock Sell Koppel Adam 3 080 237
Dec 28, 2021 Restricted Stock Units Sell Koppel Adam 3 333
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 15 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Koppel Adam 15 000
Dec 28, 2021 Common Stock Sell Weissman James B 18 100
Dec 28, 2021 Restricted Stock Units Sell Weissman James B 11 325
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 11 879
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 33 999
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 105 000
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 180 000
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 111 800
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 75 000
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 121 300
Dec 28, 2021 Employee Stock Option (Right to Buy) Sell Weissman James B 68 100
Dec 28, 2021 Common Stock Sell Smith Cynthia 3 333
Dec 28, 2021 Restricted Stock Units Sell Smith Cynthia 3 333
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Smith Cynthia 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Smith Cynthia 25 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Smith Cynthia 15 000
Dec 28, 2021 Director Stock Option (Right to Buy) Sell Smith Cynthia 15 000
Dec 28, 2021 Common Stock Sell Pagan Douglas W. 7 775
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT